Cara Therapeutics reported $42.81M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 436.58M 296.75M
Acelrx Pharmaceuticals ACRX:US USD 12.73M 2.43M
Cara Therapeutics CARA:US USD 42.81M 3.91M
Chugai Pharma 4519:JP JPY 274.04B 86.27B
Depomed DEPO:US USD 64.83M 12.56M
Endo International Ordinary Shares ENDP:US USD 1.05B 137.68M
Halozyme Therapeutics HALO:US USD 147.16M 56.23M
Horizon Pharma HZNP:US USD 2.13B 237.96M
Jazz Pharmaceuticals JAZZ:US USD 482.67M 191.74M
Neurocrine Biosciences NBIX:US USD 212.2M 48.9M
Pacira Pharmaceuticals PCRX:US USD 109.42M 12.64M
Pain Therapeutics PTIE:US USD 174.66M 22.57M
Revance Therapeutics RVNC:US USD 104.49M 35.07M
Supernus Pharmaceuticals SUPN:US USD 111.49M 61.94M
Teva Pharmaceutical Industries TEVA:US USD 2.22B 167M
Vanda Pharmaceuticals VNDA:US USD 49.4M 8.83M